ALNYLAM PHARMS INC
PharmaALNYLAM PHARMS INC is a pharmaceutical company focused on Gastroenterology. Key products include AMVUTTRA.
FDA Novel Drug Designations
(2018-2022)See 4 novel approvals →
ALNYLAM PHARMS INC at a Glance
- Growing R&D activity with 17 trials in last 2 years
- Fast trial execution (28 months median completion)
ALNYLAM PHARMS INC's Key Drugs
ALNYLAM PHARMS INC's core commercial portfolio centers on AMVUTTRA, GIVLAARI, OXLUMO, spanning Gastroenterology — its most strategically important drugs approved in the last 15 years.
Hereditary Transthyretin-Mediated Amyloidosis
Acute Hepatic Porphyria
Primary Hyperoxaluria Type 1
Hereditary Transthyretin-Mediated Amyloidosis
ALNYLAM PHARMS INC's Recent FDA Approvals
New NDA/BLA approvals for ALNYLAM PHARMS INC over the last two years — novel drugs only, excluding generics and label supplements.
ALNYLAM PHARMS INC's Therapeutic Areas
ALNYLAM PHARMS INC's approved drugs and pipeline span 1 therapeutic area, led by Gastroenterology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ALNYLAM PHARMS INC's Top Competitors
ALNYLAM PHARMS INC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ALNYLAM PHARMS INC Pipeline Snapshot
Active clinical trials for ALNYLAM PHARMS INC across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
4 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Trial Catalysts
- • Gastroenterology pipeline focus
- • 4 Phase 3 readouts tracked
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 10/15 completed
- • Speed: 28 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges